100644-65-3

Usage

Uses

Used in Pharmaceutical Industry:
4-CHLORO-1H-PYRAZOLO[3,4-D]PYRIMIDIN-6-AMINE is used as a key intermediate in the synthesis of drugs and agrochemicals for its versatile reactivity and ability to undergo various functional group transformations. It plays a crucial role in the development of new pharmaceutical compounds with potential therapeutic applications.
Used in Medicinal Chemistry Research:
As a potential kinase inhibitor, 4-CHLORO-1H-PYRAZOLO[3,4-D]PYRIMIDIN-6-AMINE is used in medicinal chemistry research to explore its therapeutic potential and develop novel drug candidates targeting specific kinases involved in various diseases.
Used in Drug Discovery:
4-CHLORO-1H-PYRAZOLO[3,4-D]PYRIMIDIN-6-AMINE is utilized in drug discovery processes to identify and optimize new chemical entities with potential therapeutic effects. Its unique structure and reactivity make it a promising candidate for the development of innovative drugs with improved efficacy and selectivity.

InChI:InChI=1/C5H4ClN5/c6-3-2-1-8-11-4(2)10-5(7)9-3/h1H,(H3,7,8,9,10,11)

Upstream product

• 5604-46-6 2-amino-4,6-dichloropyrimidine-5-carboxaldehyde 
• 85840-20-6 2-amino-4-chloro-1,6-dihydro-6-oxo-5-pyrimidinecarboxaldehyde 

Downstream Products

• 109737-96-4 6-amino-4-chloro-2-(2'-deoxy-3',5'-di-O-(p-toluoyl)-β-D-erythro-pentofuranosyl)-2H-pyrazolo<3,4-d>pyrimidine 
• 109737-95-3 6-amino-4-chloro-1-(2'-deoxy-3',5'-di-O-(p-toluoyl)-β-D-erythro-pentofuranosyl)-1H-pyrazolo<3,4-d>pyrimidine 
• 287177-82-6 1H-pyrazolo[3,4-d]pyrimidin-6-amine 
• 109737-90-8 6-amino-1-[2'-deoxy-3',5'-di-O-(p-toluoyl)-β-D-erythro-pentofuranosyl]-4-methoxy-1H-pyrazolo[3,4-d]pyrimidine 
• 100644-70-0 8-aza-7-deaza-2'-deoxyguanosine 
• 100644-68-6 6-amino-1-<2'-deoxy-3',5'-di-O-(p-toluoyl)-β-D-erythro-pentofuranosyl>-4-methoxy-1H-pyrazolo<3,4-d>pyrimidine 
• 109737-94-2 6-Amino-2-(2'-deoxy-β-D-erythro-pentofuranosyl)-2H-pyrazolo<3,4-d>pyrimidin-4(5H)-one 
• 109737-97-5 6-Amino-1-(2'-deoxy-3',5'-di-O-(p-toluoyl)-β-D-erythro-pentofuranosyl)-1H-pyrazolo<3,4-d>pyrimidin-4(5H)-thione 
• 443107-04-8 4-chloro-1-(2-fluorobenzyl)-1H-pyrazolo[3,4-d]pyrimidin-6-amine 

Relevant academic research and scientific papers

Impact of Minor Structural Modifications on Properties of a Series of mTOR Inhibitors

Minor structural modifications - sometimes single atom changes - can have a dramatic impact on the properties of compounds. This is illustrated here on structures related to known mTOR inhibitor Sapanisertib. Subtle changes in the hinge binder lead to strikingly different overall profiles with changes in physical properties, metabolism, and kinase selectivity.

ADENOSINE RECEPTOR ANTAGONIST COMPOUNDS

The present disclosure provides adenosine receptor (e.g., A2A and/or A1 receptor) antagonist compounds and compositions including said compounds. The present disclosure also provides methods of using said compounds and compositions for modulating (e.g., inhibiting or antagonizing) A2A and/or A1 receptor in a biological system. The compounds and compositions find use in various therapeutic applications including the treatment of cancer and in immuno-oncology. The compounds and compositions find use in various therapeutic applications including the treatment of central nervous system or neurodegenerative diseases, such as Parkinson's disease.

ADENOSINE A2A RECEPTOR ANTAGONISTS AND USES THEREOF

Disclosed herein are compounds, compositions, and methods for modulating the A2A2A adenosine receptor with the compounds and compositions disclosed herein. Also described are methods of treating diseases or disorders that are mediated by the A

Fused pyrimidine derivatives substituted with a nitrogen-containing heterocyclic ring and their pharmaceutical use

The present application relates to fused pyrimidine derivatives substituted with heterocycles containing nitrogen and to their medicinal use. Provided are a compound represented by chemical formula I, a solvate, a stereoisomer thereof, a pharmaceutically

Development of18f-labeled radiotracers for pet imaging of the adenosine a2a receptor: Synthesis, radiolabeling and preliminary biological evaluation

The adenosine A2A receptor (A2AR) represents a potential therapeutic target for neuro-degenerative diseases. Aiming at the development of a positron emission tomography (PET) radio-tracer to monitor changes of receptor density and/or occupancy during the

Development of pyrazolo[3,4-d]pyrimidine-6-amine-based TRAP1 inhibitors that demonstrate in vivo anticancer activity in mouse xenograft models

TNF Receptor Associated Protein 1 (TRAP1) is a mitochondrial paralog of Hsp90 related to the promotion of tumorigenesis in various cancers via maintaining mitochondrial integrity, reducing the production of reactive oxygen species, and reprogramming cellular metabolism. Consequently, Hsp90 and TRAP1 have been targeted to develop cancer therapeutics. Herein, we report a series of pyrazolo[3,4-d]pyrimidine derivatives that are mitochondria-permeable TRAP1 inhibitors. Structure-based drug design guided the optimization of potency, leading to the identification of compounds 47 and 48 as potent TRAP1 and Hsp90 inhibitors with good metabolic and plasma stability as well as acceptable CYP and hERG inhibition. X-ray co-crystallization studies confirmed both 47 and 48 interact with the ATP binding pocket in the TRAP1 protein. Compounds 47 and 48 demonstrated excellent anticancer efficiency in various cancer cells, with limited toxicity over normal hepatocyte and prostate cells. Mouse PC3 xenograft studies showed 47 and 48 significantly reduced tumor growth.

Application of five-membered heterocycle pyrimidine compound

The invention belongs to the field of medicine and particularly relates to application of a five-membered heterocycle pyrimidine compound with the structural features as shown in formula (I) and the pharmaceutically acceptable salt of the five-membered heterocycle pyrimidine compound serving as nucleotide oxidative damage repairase MTH1 inhibitors. Pharmacological experiment results show that thecompound can evidently inhibit the activity of MTH1 and can be used for preventing and treating clinical diseases related to MTH1.

nitrogen hybridization guanine nucleoside and its synthetic method and the use of DNA sequencing

The invention discloses hybrid azaguanosine as well as a synthesis method and an application thereof in DNA sequencing. The synthesis method comprises the steps: removing a protecting group of a compound as shown in formula (III) in the specification under an alkaline condition to obtain a compound as shown in formula (II) in the specification; further demethylating to obtain a compound as shown in formula (I) in the specification, i.e. 7-deaza-7-halogen-8-aza-guanosine, wherein R1 is H or OH, R2 is I, Br or Cl, and R3 is H or a compound shown in the specification. The hybrid azaguanosine disclosed by the invention is a novel reagent for DNA sequencing, which, compared to guanosine failing to substitute nitrogen on 8 sites, is more excellent in base identifying effect and more stable in DNA chain structure. Meanwhile, different from the prior art that 8-site nitrogen-substituted guanosine is complex in synthesis method, low in yield and unsuitable for commercial production, the synthesis method disclosed by the invention is easily available in raw material required, and adopts conventional chemical synthesis reaction; and the method is relatively high in yield, and suitable for wide popularization and application.

THERAPEUTICALLY ACTIVE PYRAZOLO-PYRIMIDINE DERIVATIVES

A series of pyrazolo[3,4-d]pyrimidine derivatives that are substituted at the 4- position by a diaza monocyclic, bridged bicyclic or spirocyclic moiety, are beneficial in the treatment and/or prevention of various human ailments, including inflammatory, autoimmune and oncological disorders; viral diseasesand malaria; and organ and cell transplant rejection.

METABOLITES OF 2-(FURAN-2-YL)-7-(2-(4-(4-(2-METHOXYETHOXY)PHENYL)PIPERAZIN-1-YL)ETHYL)-7H-PYRAZOLO[4,3-e][1,2,4]TRIAZOLO[1,5-c]PYRIMIDIN-5-AMINE AND THEIR UTILITY AS ADENOSINE A2a RECEPTOR ANTAGONISTS

The present invention provides a compound of the (formula:(I) or a pharmaceutically acceptable salt thereof in isolated and purified form. The compound is an adenosine A2a receptor antagonists useful in treatment of central nervous system disorders, such